
MLYS Stock Forecast & Price Target
MLYS Analyst Ratings
Bulls say
Mineralys Therapeutics has developed lorundrostat, a proprietary aldosterone synthase inhibitor, which has shown a significant placebo-adjusted blood pressure reduction exceeding 10 mmHg, a factor that is likely to attract the attention of prescribers. Comparative analysis indicates that lorundrostat possesses a robust and differentiated profile for treating uncontrolled and resistant hypertension, especially in the context of Phase 3 competitor data. Additionally, the company is positioned for near-term FDA feedback and an anticipated New Drug Application submission, further enhancing its growth potential in the biopharmaceutical market.
Bears say
Mineralys Therapeutics Inc faces significant risks that contribute to a negative outlook for its stock. Key concerns include the potential failure of its product candidate, lorundrostat, to meet peak commercial revenue estimates due to limitations in market size, penetration rates, and pricing strategies. Additionally, there is a heightened risk of financial instability stemming from the company's inability to secure necessary capital resources for operations and the ongoing challenges associated with program development and commercialization.
This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MLYS Analyst Forecast & Price Prediction
Start investing in MLYS
Order type
Buy in
Order amount
Est. shares
0 shares